Slide 1: Entera Bio Ltd. Corporate Presentation
Entera Bio Ltd. Corporate Presentation NASDAQ: ENTX 1
Slide 2: Disclaimer
Disclaimer Various statements in this presentation are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this presentation regarding our prospects, plans, financial position, business
Slide 3: Entera Vision: First-in-Class Oral Peptide Treatments
ENTERA VISION To Develop Transformative, First-in-Class Oral Peptide Treatments Our Mission Focus Where Deliver Value, Think Beyond It Matters Fast the Obvious Invest in therapeutic spaces that Drive value for patients, clinicians Think outside the box, innovate have been ignored and require and hea
Slide 4: Oral Peptides Developed to Empower Patients and Unlock Clinician Access
ENTERA COMPANY BACKGROUND Oral Peptides Developed to Empower Patients and Unlock Clinician Access Proprietary N-Tab® Platform Lead Asset – Fully Funded Through PDUFA (2030E) ▪ Innovative first-in-class oral peptides EB613 (Osteoporosis): First oral tablet designed to democratize anabolic ▪ Large (4k
Slide 5: Entera Oral Peptide Pipeline
Entera Oral Peptide Pipeline Multiple pathways to significant value creation Program Indication Target Preclinical Phase 1 Phase 2 Phase 3 Ownership* PTH (1-34) Q4/26 EB613 Osteoporosis Agonist Ph3 registrational teriparatide study initiation Acylated 2027 EB612 Hypoparathyroidism PTH (1-34) Ph1 stu
Slide 6: Entera Core Team
Entera Core Team Bringing Together Scientific Excellence to Deliver Better Treatment Outcomes Globally Felicia Cosman, MD Chair, Scientific and Miranda Toledano Gregory Burshtein, PhD Hillel Galitzer, PhD Riccardo Camisasca, MD Dana Yaacov, CPA Clinical Advisory Board Chief Executive Officer Chief S
Slide 7: N-Tab Proprietary Platform
N-Tab® Proprietary Platform 7
Slide 8: Barriers to Oral Peptide Delivery
Barriers to Oral Peptide Delivery Proteolytic Degradation PTH(1-34) Proteolysis by Pepsin PTH(1-34) Proteolysis by Trypsin 100% 100 100 100 90 01 Stomach: 80 73 80 % PTH recovered % PTH Recovered • Pepsin-mediated peptide cleavage 70 60 60 60 • Acidic pH → protein denaturation 50 40 human 40 peptide
Slide 9: Two Synergistic Mechanisms of the N-Tab Platform
UNLOCKING ORAL PEPTIDE ABSORPTION Two Synergistic Mechanisms of the N-Tab® Platform The N-Tab® platform overcomes enzymatic degradation and enhances permeability for improved bioavailability Proteolysis Inhibition Permeability Enhancement Protease Activity is Blocked. Peptide Survives. Membrane Flui
Slide 10: N-Tab: Core Platform Advantages
N-Tab®: Core Platform Advantages SCIENCE BREADTH Advantageous Clinically Proven Broad Applicability Pharmacokinetic Profile Overcomes oral bioavailability challenges of Demonstrated consistent exposure and robust Versatile platform enabling conversion of diverse peptides enabling therapeutically rel
Slide 11: EB613 Oral PTH (1-34), Teriparatide Tablet Treatment
EB613 Oral PTH (1-34), Teriparatide Tablet Treatment First Once Daily Oral Osteoanabolic for Post-Menopausal Women with Osteoporosis 11
Slide 12: EB613: First Oral Anabolic (Bone Building) Tablet
EB613: First Oral Anabolic (Bone Building) Tablet • Derisked asset, phase 3 ready with efficient path to registration • Oral tablet with identical API as blockbuster SC injection, Forteo® (Eli Lilly, approved since 2002, ~$1.7BN peak sales) • Phase 2 showed comparable efficacy/safety as Forteo • Uni
Slide 13: Osteoporosis is the Most Common Metabolic Bone Disease Worldwide
Osteoporosis is the Most Common Metabolic Bone Disease Worldwide Dysregulated Bone Remodeling: Increased Osteoclast Activity ↑ Bone resorption (CTX biomarker) Reduced Bone Formation ↓ Healty Bone Osteoporotic Bone Bone formation (P1NP biomarker) Dense trabecular structure Reduced and fragile trabecu
Slide 14: Osteoporosis Fractures Afflict More Women; Treatment Gap Persists
Osteoporosis Related Fractures Afflict More Women than Heart Attack, Breast Cancer and Stroke Combined Yet a Treatment Gap Persists Globally 200M Women worldwide 54M ~60% >2M >20% 2019 are affected by osteoporosis Americans at risk Do not accept or Osteoporosis of hip-fracture Date of last approved
Slide 15: EB613 Addresses the Treatment Gap in the Osteoporosis Patient Journey
EB613 Addresses the Treatment Gap in the Osteoporosis Patient Journey ~10M diagnosed with osteoporosis in the US, with estimated less than ~40% treated There is need for novel products with enhanced efficacy, tolerability, and ease of use – FDA (2025)* Anti-Resorptive EB613 Injectable Anabolic 1st L
Slide 16: EB613 Phase 2 Clinical Study in Postmenopausal Women with Osteoporosis
EB613 Phase 2 Clinical Study in Postmenopausal Women with Osteoporosis 6-month, randomized, dose-ranging, placebo-controlled study in postmenopausal women with osteoporosis - met primary and secondary endpoints Key Inclusion Criteria Placebo QD Primary Endpoint 50+ years old EB613 0.5 mg QD Serum PI
Slide 17: EB613 Rapidly Induces Bone Formation (P1NP) while Reducing Resorption (CTX)
EB613 Rapidly Induces Bone Formation (P1NP) while Reducing Resorption (CTX) EB613’s dual mechanism stimulates new bone formation on trabecular and cortical (periosteal and/or endosteal) bone surfaces by preferential stimulation of osteoblastic activity over osteoclastic activity EB613 (2.5 mg) Shows
Slide 18: EB613 Produced Statistically Significant Increases in BMD across All Skeletal Sites
EB613 Produced Statistically Significant Increases in BMD across All Skeletal Sites - with a Clear Dose Response Placebo Adjusted BMD for EB613 vs. Published Forteo® Data in a Similar Patient Population 4 3.8 3.9 EB613 2.5mg Titrated Change from Baseline 2.9 EB613 2.5mg 3 Non Titrated 2.4 Forteo® 2.
Slide 19: EB613 Produced Comparable Total Hip BMD Increases as Forteo
EB613 Produced Comparable Total Hip BMD Increases as Forteo® 6 Month Published Data Total Hip BMD is an FDA Efficacy Endpoint as of 12/19/2025 2.5 Forteo® EB613 2.07 2 % Change from Baseline 1.84 1.5 1.44 1.57 1.34 1.13 1 0.5 0.5 0.1 0 Leder 2015 Miller 2016 Pooled 2.5mg Titrated 2.5mg Placebo Adjus
Slide 20: Exploratory Data Support the Dual Mechanism; Subgroup Signal in Early Menopause
Exploratory Data Support the Dual Mechanism; Subgroup Signal in Early Menopause Post-hoc EB613 Phase 2 analysis: BMD Effects of EB613 on Trabecular outcomes by time since last menstrual and Cortical Bone Using 3D-DXA period (LMP) Average Cortical Surface BMD % Change from Baseline to Month 6 for EB6
Slide 21: EB613 Has Been Well-Tolerated Across the Phase 1/2 Program
EB613 Has Been Well-Tolerated Across the Phase 1/2 Program No new drug-related safety signals identified to date, supporting advancement into Phase 3 N = 270 6 months 0% Up to 9mg Total Exposed Duration of Exposure SAE Rate Related to EB613 Dose Overall Tolerability and Safety Summary of Cross-over
Slide 22: EB613 Phase 2 Safety Profile in Patients with Osteoporosis
EB613 Phase 2 Safety Profile in Patients with Osteoporosis Titration substantially reduced drug-related adverse events (ENT-07-2019) • Discontinuations due to mild and moderate orthostatic symptoms (headache, nausea, palpitations, dizziness): 21% with EB613 2.5 mg constant vs 0% with EB613 2.5 mg ti
Slide 23: Phase 1 Bridging Study - Comparable PK Exposure Profile
Phase 1 Bridging Study - Comparable PK Exposure Profile Resulting in Comparable PD Outcome, Supports Advancement of EB613 Single Tablet into Phase 3 EB613 single tablet showed similar PK profile to Change in Serum Ca from Change in PTH(1-84) from multi-tablet EB613 treatment tested in Phase 2 study
Slide 24: EB613 Phase 3 Design and Proposed Registrational Strategy
EB613 Phase 3 Design and Proposed Registrational Strategy 24
Slide 25: EB613 Phase 3 Development Plan
EB613 Phase 3 Development Plan Double-Blind Registrational Study Extension Study R EB613 (N = 250) out to 24M EB613 3 mg (N = 500) 12M Screening Period Safety Follow-up 1:1 Antiresorptive SoC (N = 250) for 12M R 2:1 Placebo (N= 250) 12M EB613 (N = 250)* *Draft schema for placebo transition during th
Slide 26: EB613 Patient and Clinician Surveys
EB613 Patient and Clinician Surveys 26
Slide 27: Why an Oral Osteoanabolic? Why Now?
Why an Oral Osteoanabolic? Why Now? Persistent treatment chasm Access • 1 in 3 women over age 50 will experience a There are major barriers to fracture in their lifetime prescribing currently approved • Yet more than 80% will not receive injectable anabolics, only available treatment after a fractur
Slide 28: The Market is Primed for EB613: Multiple Tailwinds Drive Uptake
The Market is Primed for EB613: Multiple Tailwinds Drive Uptake US Current Osteoporosis Patient Pool EB613: First and Only Once-Daily Oral Anabolic in Development 13 M HCP SURVEYS Prevalent • GYNs, PCPs, Rheums and Endos likely to prescribe 80% Dx rate • Oral administration and known mechanism suppo
Slide 29: EB613 Addresses the Treatment Gap: Survey Supports Cross-Specialty Demand
EB613 Addresses the Treatment Gap in the Osteoporosis Patient Journey Survey supports broad, cross-specialty prescriber demand A new oral anabolic agent poised to EB613 White Space - A Game-Changing Treatment in Osteoporosis transform osteoporosis treatment ▪ Survey results demonstrate strong EB613
Slide 30: OB/GYN Practices Are the Natural Hubs for Advocacy of Women's Bone Health
OB/GYN and GYN Practices Are the Natural Hubs for Advocacy of Women’s Bone Health GYN Osteoporosis Treatment Selection Reflects the Underutilization and Limited Market Penetration of Injectable Anabolics 89% Alendronate of respondents routinely Risedronate include bone health (DXA Ibandronate scans)
Slide 31: An Oral Anabolic Tablet Dramatically Shifts OB/GYN Willingness to Prescribe
An Oral Anabolic Tablet like EB613 Dramatically Shifts OB/GYN and GYN Willingness to Prescribe Of treaters who do not use injectable anabolics (n=63), In treaters of osteoporosis (n=75), 92% would prescribe an oral anabolic from 12% to 92% Of treaters using injectable anabolics (n=10), 100% would pr
Slide 32: EB612 Program
EB612 Program First Daily Oral Acylated PTH(1-34) Replacement Therapy for the Treatment of Hypoparathyroidism In Co-Development with OPKO 32
Slide 33: Hypoparathyroidism: Significant Unmet Need Remains
Hypoparathyroidism: Significant Unmet Need Remains Current therapies leave the majority of patients inadequately controlled or burdened by daily injections >200K ~75% Daily Patients (US + EU) Post-surgical cases Injection burden Predominantly women Thyroid /Parathyroid surgery Palopegteriparatide (Y
Slide 34: EB612: Acylated PTH(1-34) Analog Designed for Once-Daily Oral Dosing
EB612: Acylated PTH(1-34) Analog Designed for Sustained, Once-Daily Oral Dosing for Hypoparathyroidism A Oral Tablet Absorption B Albumin Binding Extends C Sustained PTH Systemic Drug Half-life N-Tab® protects EB612 from GI degradation and Conjugated fatty-acid (acylation) enables reversible Gradual
Slide 35: EB612: Sustained Serum Calcium Control: Cross-Species Validation
EB612: Sustained Serum Calcium Control: Cross-Species Validation Full Calcium Normalization Prolonged PK Profile Sustained Calcemic Effect TPTx rat Minipig model Non-human Primate model Sham Vehicle LA-PTH(1-34) 1.5 10 2.5 16 Mean (SE) Ca (Alb) change from Mean (SE) LA-PTH(1-34) plasma Mean (SE) ser
Slide 36: GLP1/Glucagon & GLP2 Programs
GLP1/Glucagon & GLP2 Programs In Co-Development with OPKO 36
Slide 37: EB618: Preclinical Package Supports First Oral Once-Daily GLP-1/Glucagon Agonist
EB618: Preclinical Package Supports the First Oral, Once-Daily GLP-1/Glucagon Agonist for Patients with Metabolic Disorders GLP-1 therapies surpassed $40 billion in sales in 2024 and the opportunity for oral agents remains significant Oral OXM Tablets in Minipigs 450 Mean Plasma Concentration (ng/ml
Slide 38: First Oral GLP-2 Tablet Demonstrates Sustained Systemic Exposure
First Oral GLP-2 Tablet Demonstrates Sustained Systemic Exposure Supporting Once-Daily Dosing for SBS A validated GLP-2 target, a ~$800M GATTEX market, and an opportunity to transform treatment for ~30K SBS patients across the US & EU Extended Plasma Half-Life: Approximately 15 hours, an 18-fold 200
Slide 39: Thank you
Thank you I N V E S T O R R E L AT I O N S IR@enterabio.com Nasdaq: ENTX | www.enterabio.com 39